EHA 2024 Insights: Treatment of Advanced Stage, High-Risk Hodgkin's …

Insights from 2024 EHA Annual Meeting

M. Salamoon

SOHO 2021 Next Questions in Hodgkin Lymphoma

Society of Hematologic Oncology Ninth Annual Meeting (SOHO 2021)

C. Moskowitz

2022 Sedona ASCO Updates on the Frontline Hodgkin Lymphoma: 1L Chemo…

Total Health

B. Haverkos

The Potential Role of ctDNA in Hodgkin Lymphoma Management

XIV Eurasian Hematology-Oncology Congress - EHOC 2023

I. Panovska-Stavridis

SOHO Turkey 2023: How I Treat Hodgkin Lymphoma

SOHO Turkey 2023

T. Toptas

ASH 2023 Insights: "BrECADD Combined With PET2-Guided Treatment for …

ecancer

P. Borchmann

Brentuximab Vedotin + AVD vs. ABVD in Advanced cHL: What Is the 5-Ye…

David Straus

What Is Nodular Lymphocyte Predominant Hodgkin Lymphoma and How Do Y…

PrecisCa

J. Abramson

Classical Hodgkin Lymphoma: Subtypes and Differential Diagnosis

Judith Ann Ferry

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

Shingles (Herpes Zoster) Vaccination in Adults: What is the Importan…

William Schaffner

Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL): Clinical an…

Judith Ann Ferry

EHA 2024 Insights: Limited Stage HL - Current SOC, Future Directions…

Insights from 2024 EHA Annual Meeting

S. Park

Update on Benzene in Dermatology Products

Masterclasses in Dermatology

C. Bunick

Updates on Allogeneic Stem Cell Transplant

Yale Cancer Center

L. Bachegowda

ASCO® 2023 Insights: "SWOG S1826, a Randomized Study of Nivo-AVD vs.…

Insights from 2023 ASCO® Annual Meeting

A. Herrera

Post-Acute Outcomes After HL: An Epidemiologic Perspective

19th Annual International Ultmann Chicago Lymphoma Symposium

L. Morton